Patents by Inventor Nathalie Norais
Nathalie Norais has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230266317Abstract: The present invention relates to in vitro assays, more particularly ELISA assays. Said ELISA assays comprise antibodies capable of binding Ubiquitous surface protein A2 (UspA2) from Moraxella catarrhalis. The present invention relates to assays for assessing the binding of antibodies to UspA2 and the relative potency of vaccine test samples comprising UspA2. In particular, the invention relates to in vitro relative potency assays used in the release of vaccine that comprises UspA2 to the public.Type: ApplicationFiled: September 9, 2020Publication date: August 24, 2023Applicant: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Michael CHAPLET, Nathalie NORAIS, Simona RONDINI, Silvia ROSSI PACCANI
-
Publication number: 20220257751Abstract: The present invention provides analytical tools for the characterisation of bioconjugates, in particular for the measurement of glycosylation levels, and methods for absolute quantification of glycosylation sequences, as well as sequences and glycosylation sites for use in such methods.Type: ApplicationFiled: July 21, 2020Publication date: August 18, 2022Applicant: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Massimilliano BIAGINI, Lucia Eleonora FONTANA, Anna GALEA, Nathalie NORAIS, Maria SCARSELLI
-
Publication number: 20220221455Abstract: The present invention relates to the field of antigen binding proteins and the use of such antigen binding proteins in an assay. More particularly, it relates to antigen binding proteins which bind to an epitope of Protein E and antigen binding proteins which bind to an epitope of PilA. The present invention also relates to assays (particularly in vitro assays) for assessing binding to Protein E and/or PilA and the potency of vaccines containing Protein E and/or PilA. In particular the invention relates to in vitro relative potency assays used in the release of a vaccine to the public.Type: ApplicationFiled: April 16, 2020Publication date: July 14, 2022Applicant: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Nathalie NORAIS, Silvia ROSSI PACCANI, Simona RONDINI
-
Patent number: 10864262Abstract: Gram-negative bacterial strains are generated by inactivating at least one LytM catalytic domain-containing protein, such as NT013, NT017 and NT022 of non typeable H influenzae. The vesicles from these strains are useful for vaccination.Type: GrantFiled: April 24, 2014Date of Patent: December 15, 2020Assignee: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Maria Arico, Giuseppe Ercoli, Nathalie Norais, Marco Soriani, Chiara Tani
-
Publication number: 20190290748Abstract: NTHI protein antigens have been identified and found to be conserved across several Haemophilus influenzae pathogenic strains. They have been isolated, cloned from a reference strain and tested for immunogenicity. Methods for immunization and vaccines derived thereof are also disclosed.Type: ApplicationFiled: March 25, 2019Publication date: September 26, 2019Applicant: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Marco SORIANI, Maria SCARSELLI, Nathalie NORAIS, Danilo GOMES MORIEL, Silvia ROSSI PACCANI
-
Patent number: 10336794Abstract: Knockout of the meningococcal mltA homolog gives bacteria that spontaneously release vesicles that are rich in immunogenic outer membrane proteins and that can elicit cross-protective antibody responses with higher bactericidal titres than OMVs prepared by normal production processes. Thus the invention provides a bacterium having a knockout mutation of its mltA gene. The invention also provides a bacterium, wherein the bacterium: (i) has a cell wall that includes peptidoglycan; and (ii) does not express a protein having the lytic transglycosylase activity MltA protein. The invention also provides compositions comprising vesicles that, during culture of bacteria of the invention, are released into the culture medium.Type: GrantFiled: September 7, 2017Date of Patent: July 2, 2019Assignee: GLAXOSMITHKLINE BIOLOGICALS S.A.Inventors: Jeannette Adu-Bobie, Mariagrazia Pizza, Nathalie Norais, Germano Ferrari, Guido Grandi
-
Patent number: 10279026Abstract: NTHI protein antigens have been identified and found to be conserved across several Haemophilus influenzae pathogenic strains. They have been isolated, cloned from a reference strain and tested for immunogenicity. Methods for immunization and vaccines derived thereof are also disclosed.Type: GrantFiled: April 24, 2013Date of Patent: May 7, 2019Assignee: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Marco Soriani, Maria Scarselli, Nathalie Norais, Danilo Gomes Moriel, Silvia Rossi Paccani
-
Patent number: 10195263Abstract: An effective Staphylococcus aureus vaccine may require several antigenic components, and so various combinations of S. aureus antigens are identified for use in immunisation. These polypeptides may optionally be used in combination with S. aureus saccharides.Type: GrantFiled: May 8, 2017Date of Patent: February 5, 2019Assignee: GLAXOSMITHKLINE BIOLOGICALS S.A.Inventors: Fabio Bagnoli, Massimiliano Biagini, Luigi Fiaschi, Guido Grandi, Ravi Pratap Narayan Mishra, Nathalie Norais, Maria Scarselli
-
Publication number: 20180298064Abstract: Disclosed herein are various open reading frames from a strain of E. coli responsible for neonatal meningitis (MNEC), and a subset of these that is of particular interest for preparing compositions for immunising against MNEC infections.Type: ApplicationFiled: June 26, 2018Publication date: October 18, 2018Applicants: GlaxoSmithKline Biologicals SA, J. Craig Venter Institute, Inc.Inventors: Vega MASIGNANI, Danilo Gomes MORIEL, Francesco BERLANDA SCORZA, Nathalie NORAIS, Maria Rita FONTANA, Mariagrazia PIZZA, Laura SERINO, Hervé TETTELIN
-
Patent number: 10035826Abstract: Disclosed herein are various open reading frames from a strain of E. coli responsible for neonatal meningitis (MNEC), and a subset of these that is of particular interest for preparing compositions for immunizing against MNEC infections.Type: GrantFiled: May 9, 2016Date of Patent: July 31, 2018Assignees: GlaxoSmithKline Biologicals SA, J. Craig Venture Institute, Inc.Inventors: Vega Masignani, Danilo Gomes Moriel, Francesco Berlanda Scorza, Nathalie Norais, Maria Rita Fontana, Mariagrazia Pizza, Laura Serino, Herve Tettelin
-
Publication number: 20180009852Abstract: Knockout of the meningococcal mltA homolog gives bacteria that spontaneously release vesicles that are rich in immunogenic outer membrane proteins and that can elicit cross-protective antibody responses with higher bactericidal titres than OMVs prepared by normal production processes. Thus the invention provides a bacterium having a knockout mutation of its mltA gene. The invention also provides a bacterium, wherein the bacterium: (i) has a cell wall that includes peptidoglycan; and (ii) does not express a protein having the lytic transglycosylase activity MltA protein. The invention also provides compositions comprising vesicles that, during culture of bacteria of the invention, are released into the culture medium.Type: ApplicationFiled: September 7, 2017Publication date: January 11, 2018Applicant: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Jeannette ADU-BOBIE, Mariagrazia PIZZA, Nathalie NORAIS, Germano FERRARI, Guido Grandi
-
Publication number: 20170340720Abstract: An effective Staphylococcus aureus vaccine may require several antigenic components, and so various combinations of S. aureus antigens are identified for use in immunisation. These polypeptides may optionally be used in combination with S. aureus saccharides.Type: ApplicationFiled: May 8, 2017Publication date: November 30, 2017Applicant: GlaxoSmithKline Biologicals SAInventors: Fabio BAGNOLI, Massimiliano BIAGINI, Luigi FIASCHI, Guido GRANDI, Ravi Pratap Narayan MISHRA, Nathalie NORAIS, Maria SCARSELLI
-
Patent number: 9771399Abstract: Knockout of the meningococcal mltA homolog gives bacteria that spontaneously release vesicles that are rich in immunogenic outer membrane proteins and that can elicit cross-protective antibody responses with higher bactericidal titers than OMVs prepared by normal production processes. Thus the invention provides a bacterium having a knockout mutation of its mltA gene. The invention also provides a bacterium, wherein the bacterium: (i) has a cell wall that includes peptidoglycan; and (ii) does not express a protein having the lytic transglycosylase activity MltA protein. The invention also provides compositions comprising vesicles that, during culture of bacteria of the invention, are released into the culture medium.Type: GrantFiled: October 29, 2015Date of Patent: September 26, 2017Assignee: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Jeannette Adu-Bobie, Mariagrazia Pizza, Nathalie Norais, Germano Ferrari, Guido Grandi
-
Patent number: 9642904Abstract: An effective Staphylococcus aureus vaccine may require several antigenic components, and so various combinations of S. aureus antigens are identified for use in immunisation. These polypeptides may optionally be used in combination with S. aureus saccharides.Type: GrantFiled: December 7, 2015Date of Patent: May 9, 2017Assignee: GlaxoSmithKline Biologicals SAInventors: Fabio Bagnoli, Massimiliano Biagini, Luigi Fiaschi, Guido Grandi, Ravi Pratap Narayan Mishra, Nathalie Norais, Maria Scarselli
-
Publication number: 20160244489Abstract: Disclosed herein are various open reading frames from a strain of E. coli responsible for neonatal meningitis (MNEC), and a subset of these that is of particular interest for preparing compositions for immunising against MNEC infections.Type: ApplicationFiled: May 9, 2016Publication date: August 25, 2016Applicants: GlaxoSmithKline Biologicals SA, J. Craig Venter Institute, Inc.Inventors: Vega MASIGNANI, Danilo Gomes MORIEL, Francesco BERLANDA SCORZA, Nathalie NORAIS, Maria Rita FONTANA, Mariagrazia PIZZA, Laura SERINO, Herve TETTELIN
-
Publication number: 20160158335Abstract: An effective Staphylococcus aureus vaccine may require several antigenic components, and so various combinations of S. aureus antigens are identified for use in immunisation. These polypeptides may optionally be used in combination with S. aureus saccharides.Type: ApplicationFiled: December 7, 2015Publication date: June 9, 2016Applicant: GlaxoSmithKline Biologicals SAInventors: Fabio BAGNOLI, Massimiliano BIAGINI, Luigi FIASCHI, Guido GRANDI, Ravi Pratap Narayan MISHRA, Nathalie NORAIS, Maria SCARSELLI
-
Patent number: 9334313Abstract: Disclosed herein are various open reading frames from a strain of E. coli responsible for neonatal meningitis (MNEC), and a subset of these that is of particular interest for preparing compositions for immunizing against MNEC infections.Type: GrantFiled: June 2, 2014Date of Patent: May 10, 2016Assignee: GlaxoSmithKline Biologicals SAInventors: Vega Masignani, Danilo Gomes Moriel, Francesco Berlanda Scorza, Nathalie Norais, Maria Rita Fontana, Mariagrazia Pizza, Laura Serino, Herve Tettelin
-
Publication number: 20160108094Abstract: Knockout of the meningococcal mltA homolog gives bacteria that spontaneously release vesicles that are rich in immunogenic outer membrane proteins and that can elicit cross-protective antibody responses with higher bactericidal titres than OMVs prepared by normal production processes. Thus the invention provides a bacterium having a knockout mutation of its mltA gene. The invention also provides a bacterium, wherein the bacterium: (i) has a cell wall that includes peptidoglycan; and (ii) does not express a protein having the lytic transglycosylase activity MltA protein. The invention also provides compositions comprising vesicles that, during culture of bacteria of the invention, are released into the culture medium.Type: ApplicationFiled: October 29, 2015Publication date: April 21, 2016Applicant: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Jeannette ADU-BOBIE, Mariagrazia PIZZA, Nathalie NORAIS, Germano FERRARI, Guido GRANDI
-
Publication number: 20160067326Abstract: Gram-negative bacterial strains are generated by inactivating at least one LytM catalytic domain-containing protein, such as NT013, NT017 and NT022 of non typeable H influenzae. The vesicles from these strains are useful for vaccination.Type: ApplicationFiled: April 24, 2014Publication date: March 10, 2016Applicant: GlaxoSmithKline Biologicals s.a.Inventors: Maria ARICO, Giuseppe ERCOLI, Nathalie NORAIS, Marco SORIANI, Chiara TANI
-
Patent number: 9205142Abstract: An effective Staphylococcus aureus vaccine may require several antigenic components, and so various combinations of S. aureus antigens are identified for use in immunization. These polypeptides may optionally be used in combination with S. aureus saccharides.Type: GrantFiled: February 3, 2014Date of Patent: December 8, 2015Assignee: GlaxoSmithKline Biologicals SAInventors: Fabio Bagnoli, Massimiliano Biagini, Luigi Fiaschi, Guido Grandi, Ravi Pratap Narayan Mishra, Nathalie Norais, Maria Scarselli